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ABSTRACT Morphine spin labeled on the phenolic hydroxy group has been prepared
using commercially available reagents and characterized by thin layer chromatography,
mass spectroscopy, and electron spin resonance spectroscopy. It has been shown that
morphine modified in this way retains some opiate activity, does not pass through the
blood-brain barrier, and specifically binds to isolated rat brain synaptosomes. Spin
labeled morphine has been shown to be an effective biophysical probe complementing
radioactive tracer techniques in the study of the narcotic receptor site.
INTRODUCTION
Numerous investigations have recently demonstrated the existence of receptors in the
central nervous system which stereospecifically bind opiates (for a recent review, see
ref. 1). In all such binding studies, radiolabeled narcotic agonists or antagonists have
been used. Thus, unbound labeled material has to removed by procedures which may
destroy evidence of weak but potentially important opiate-receptor interaction (1). On
the other hand, because of the nature of spin label probes, electron spin resonance
(ESR) spectra of both bound and unbound probe can be obtained simultaneously
within certain concentration limits so that separation of bound and free opiate is not
necessary. The spin label technique is thus complementary to radiolabel investiga-
tions of the opiate receptor site.
Early studies (2) on the pharmacologic role played by various regions of the mor-
phine molecule suggested that the cationic form of the tertiary amine and the Xr molec-
ular orbital of the aromatic ring (see Fig. 1) associate with an appropriately shaped
receptor surface by ionic and van der Waals forces. The edge of the molecule com-
posed of carbons 8 through 5 and including the hydroxyls on the 3 and 6 positions,
would then be on the opposite side of the molecule from the proposed interacting
regions. Knowing that this early model might be incomplete (1), it was felt, nonethe-
less, that the most reasonable molecular site for the incorporation of a noninterfering
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FIGURE 1 Perspective drawing of spin labeled morphine. The interacting surface of the morphine
molecule according to Beckett and Casy's model (2) is on the top side in this drawing. The num-
bering system for the morphine molecule is indicated here. See text for further discussion.
spin label group would lie somewhere on this back-side edge. Thus, the 7,8-double
bond, the 6-hydroxy, and the 3-hydroxy were potential labeling sites.
Morphine spin labeled on the 3 position (3-SLM) is commercially available as part
of a spin immunoassay kit for urinary morphine detection (3-5). We describe a simple
and inexpensive method for the preparation of 3-SLM and show some of its charac-
teristics in vitro and in vivo.
MATERIALS AND METHODS
Chemicals
Morphine free base (I) was obtained from Mallinckrodt Chemical Works, St. Louis, Mo. and
used as such. The iodoacetamide nitroxides, 3-(2-iodoacetamido)-2,2,5,5-tetramethyl-1-pyr-
rolidinyloxyl (Ila) and 4-(2-iodoacetamido)-2,2,6,6-tetramethyl-1-piperidinooxyl (Ilb), and the
FRAT' reagents were purchased from SYVA Corporation, Palo Alto, Calif. and used without
further purification. Nalorphine HCI (Nalline HCI) was obtained from Merck, Sharp & Dohme,
I Trade names are given for the convenience of the reader and do not constitute an endorsement of the prod-
uct by the authors or the U.S. Government.
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West Point, Pa., and levorphanol tartrate was kindly supplied by Hoffman-LaRoche, Inc.,
Nutley, N.J.
Synthesis
The synthetic scheme followed for the preparation of 3-SLM is as follows:
H O
H0~~~~~~~~~~~~~~~~~~~~~~~~II
N6H2I OH /MeOH >NNCH3
0
~~~~+I___CHl3 N650 00NH
0
I IIa IIIa
Morphine-free base (I) (22 mg, 0.077 mmol) was dissolved in methanol (I ml) and freshly
prepared KOH (4.3 mg, 0.077 mmol) in methanol (1 ml) was added. Then Ila (25 mg, 0.077
mmol) in methanol (1 ml) was added dropwise to the stirring solution and upon completion the
reaction mixture was gently refluxed for 4 h.2 The reaction mixture was evaporated to dryness
under reduced pressure, redissolved in methanol, and applied to preparative TLC plates (Brink-
man Silica Gel HF254) which were developed in EtAc/MeOH/NH4OH (17:2:1). In this
system the morphine had an Rf = 0.26 and the SLM had an Rf = 0.43. The band correspond-
ing to the SLM was scraped off the plate and the SLM was eluted from the silica gel with
EtAc/MeOH (80:20). The eluant was evaporated to a yellow oil under reduced pressure.
Either Ila or IIb could be attached to morphine in this way.
A perspective drawing of the reaction product (Illa) is presented in Fig. 1. The configuration
of morphine is based on X-ray crystallographic data obtained on morphine hydroiodide dihy-
drate (6). The sketch of the nitroxide derivative of iodoacetamide is adapted from theoretical
and experimental studies (7, 8). We have no knowledge of the orientation of the spin label in
relation to the remainder of the SLM molecule but presume freedom of rotation about the ether
linkage at the 3 position. The spin label moiety can thus occupy a back-side position on
morphine.
Mass Spectroscopic Analysis
Mass spectra of the TLC-purified reaction product (IIIa) were obtained via direct insertion
probe on a Hewlett-Packard 5930A dodecapole mass spectrometer (Hewlett-Packard Co., Palo
Alto, Calif.). The ion source was maintained at 180° while the probe temperature was slowly
varied from ambient to 300°; spectra of 3-SLM were obtained at 250°. An ionizing current of
300 AA was employed in conjunction with an electron energy of either 70 eV or 12.5 eV.
ESR Spectroscopy
ESR analyses were performed on an X-band spectrometer (E-9, Varian Associates, Palo Alto,
Calif.) using either a TE104 dual cavity or a TEO,, cylindrical cavity when indicated. Un-
less otherwise specified, 100 kHz modulation frequency at 2 G modulation amplitude was em-
2Morphine plus one equivalent of base generates a phenoxide anion at the three position and insures nucleo-
philic displacement by this site.
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ployed. Using the dual cavity, it was found that power saturation of the nitroxide triplet began
at about 40 mW incident power when the sample was held in a capillary tu:e suspended by a
quartz ESR tube within a quartz variable temperature insertion Dewar. Thus 40 mW was the
usual power employed. When the cylindrical cavity was used, 10 mW incident power was
employed. Sample holders included the standard flat cell, the low temperature flat cell (James F.
Scanlon Co., Solvang, Calif.) or the FRAT capillary tube. In controlled temperature studies
(vide infra) a variable temperature Dewar (Scanlon) was used with a controlled temperature
apparatus (Varian) and the temperature was checked using a Cu-Constantan thermocouple and
found to be constant within 1.5'. Free radical concentrations were determined using an
on-line digital computer (Varian S-122) to perform double integrations of both unknown and
standard spin label samples. The S-122 was also used to measure the line widths necessary for
rotational correlation time determinations.
Preliminary Biological Studies
In Vivo Injections of 3-SLM. Male weanling mice were intraperitoneally (i.p.) in-
jected with 3-SLM in 0.9 ml normal saline, pH 7.5 at a dosage of 24 mg/kg morphine equiva-
lents. Controls were injected with normal saline. Animals were observed for 1 hr for evidence
of grossly apparent opiate induced behavioral or physiological effects (lethargy, staggering,
respiratory depression, altered threshold to tail clamping).
In another set of experiments, male weanling mice were injected intracerebrally (right central
hemisphere, frontal lobe) with 0.2 ml 3-SLM in normal saline, pH 7.5, at a dosage of 0.30 mg/kg
morphine equivalents. Controls were injected with 0.2 ml normal saline. The animals were
observed for grossly apparent behavioral and physiological effects as before.
Intraventricular injections of 3-SLM in adult male Sprague-Dawley rats, 250-300 g (Simonsen
Labs., Gilroy, Calif.) were also performed. Using reported coordinates (9), 30 M1l of 3-SLM
in normal saline, pH 7.5, at a dosage of 0.05 mg/kg morphine equivalents was injected. 30 min
postinjection the animals were sacrificed by decapitation and the brains were rapidly removed
and placed in cold (0-4) 0.32 M sucrose, 0.05 M Tris-HCI, pH 7.5. Brains from six animals
were pooled and homogenized (six strokes at 800 rpm), then centrifuged at 12,000 g for 30 min
in a Sorvall Model RC-2 centrifuge (DuPont Instruments, Sorvall Op^rations, Newtown,
Conn.). The supernate and pellet were separated for subsequent ESR analyses. Animals were
also injected with 3-SLM intraperitoneally rather than intraventricularly to determine general
organ distribution patterns in liver, heart, and brain. Adult male rats, as before, were injected
i.p. with 0.9 ml 3-SLM in normal saline at 50 mg/kg morphine equivalents. Animals were
sacrificed 15 min postinjection and the brain, liver, and heart rapidly removed and placed in
0.32 M sucrose as in previous experiments. The organs were homogenized at 800 rpm as before
and aliquots of the whole organ homogenates were taken for ESR analyses.
In Vitro Synaptosomal Studies. Male Sprague-Dawley rats, 250-300 g, were sacrificed
by decapitation and the brains rapidly removed and placed in 0.32 M sucrose, 0.05 M Tris-HCI,
pH 7.5 at 0-4°. Synaptosomes were isolated by differential and density gradient ultracentrifu-
gation methods (10, 11). In four successive experiments, synaptosomes containing 8.4, 9.0,
10.0, and 10.5 mg/ml protein (biuret [12]), in 0.32 M sucrose, pH 7.5 (Tris-HCI, 0.05 M),
were incubated with 3-SLM. 1 ml aliquots of synaptosome suspensions were incubated in a
Dubnoff metabolic shaker under the following conditions: (A) 3-SLM, I MM, at 0'; (B) 3-SLM,
1 IM, + nalorphine, I mM, at 0'; (C) 230 for 5 min, + 3-SLM, 1 gM, at 23' for 10 min;
(D) nalorphine, 1 mM, for 5 min at 23', + 3-SLM, I gM, 10 min at 23'. Incubations were
terminated by placing the samples in ice-water slurries at 0'. Samples were kept at 0' until
ESR observations (40) were made using the small flat cell and variable temperature apparatus
described previously.
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FIGURE 2 Mass spectrum of 3-spin labeled morphine. The mass spectrum was obtained at 70 eV
by controlled fractional vaporization of TLC-purified 3-SLM from a probe directly inserted into
the ion source of a Hewlett-Packard 5930A dodecapole mass spectrometer.
RESULTS
Characterization of Spin Labeled Morphine
Mass Spectrometry. The fragmentation pattern shown in Fig. 2 resulted at
70 eV and is in all respects characteristic of the proposed product. The peak due to the
molecular ion (m/e 482) is readily apparent. The M+ 1 peak is much more intense than
would be expected from the contribution of normally encountered isotopes (85% in-
stead of the expected 31% of the molecular ion); this may be partly due to hydrogen
radical abstraction from water adsorbed in the ion source or glass capillary sample
holder by the even electron molecular ion species3 (13, 14). The mass spectrum also
offers strong evidence that the spin label has been attached to the 3 position rather
than the 6 position. The peak at m/e 465 indicates loss of a hydroxyl radical from C-6
(see Fig. 1 for numbering), a cleavage that is common to the mass spectra of those
morphine alkaloids that possess a 6-hydroxyl allylic to the 7,8 double bond (15). Also
present are relatively intense peaks at m/e 124 and 162 which denote an unsubstituted
6-hydroxyl in ring C. Ions indicative of an unsubstituted phenol at the 3 position are
not present or are found one mass unit lower than expected, e.g., m/e 284 and 214.
This suggests cleavage of the spin label followed by fragmentation of the alkaloid
nucleus. In addition, a ferric chloride test gave no indication of the presence of the
free phenol.
Although the fragmentation of the alkaloid part of the molecule is readily apparent,
the mass spectrum is dominated by cleavage occurring in the spin label moiety. The
presence of a tetramethylpyrrolidine nitroxide is clearly visible from the high mass end
of the spectrum4 (14). The peak at m/e 467 indicates loss of a methyl radical, while
m/e 452 denotes loss of an additional methyl radical or extrusion of NO from the
3A greatly simplified spectrum resulted at 12.5 eV with a relative decrease in the intensity of the M+ I peak
compared to the molecular ion peak. This indicates that there is not an analogous impurity present, e.g., the
corresponding hydroxylamine (which would also possess a much more intense M-15 peak at m/e 468) and
that the ion in question requires considerable energy for its formation.
4J. A. Kelley and J. A. Cella, unpublished results.
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molecular ion. No peak is seen corresponding to the elimination of isobutene from the
molecular ion, but m/e 396 does indicate loss of both C4H8 and NO. An intense peak
at m/e 409 (M-73, a rearrangement involving loss of C3H7NO) is also common to this
class ofcompounds (14).
ESR Spectroscopy. Fig. 3 A shows a typical ESR spectrum of 3-SLM (lIIa)
in aqueous solution (4.2 x 10-5 M). Also shown (Fig. 3 B) is the spectrum of the
iodoacetamide spin label (IIa) used to label the morphine in aqueous solution (3.0 x
10-1 M). The isotropic constants, A. and gO (15.9 G and 2.0056, respectively) were
identical for the two compounds. However, the rotational correlation time, T =
1.395 x 10-8 [AH(+ 1) + AH(- 1) - 2AH(0)] s (16, 17) where AH is the line width at
half height in gauss atM = + 1, -1, and 0, respectively, of the actual absorption spec-
trum, did increase when the spin label was attached to morphine (rIIa = 5.2 x 10-10 s;
IAo= 5 9 gouss-l
go= 2.0056
A
1-Ao= 15 9 gouss-1
B
FIGURE 3 (A) First derivative ESR spectrum of a 4.2 x 10 5 M aqueous solution of 3-SLM.
The spectrum was obtained using a TE-01, cylindrical cavity with the sample in a capillary tube.
The incident power was 10mW and the 100 kHz modulation frequency had an amplitude of 0.1 G.
The field was swept at 3 G/min using a 0.3 s filter time constant. The spectral data were pro-
cessed directly by an on-line digital computer to obtain line widths at half height of the absorp-
tion peaks which were 0.720, 0.707, and 0.782 G for the M = + 1, 0, and - I hyperfine lines,
respectively. These values were used as described in the text to calculate the rotational correla-
tion time. The isotropic constants, Ao and go, are indicated. (B) First derivative ESR spectrum
of a 3.0 x 10-5 M aqueous solution of the pyrrolidine nitroxide iodoacetamide derivative used
to label 3-SLM. The observation conditions were the same as in A. The corresponding line
widths at half height were 0.682, 0.682, and 0.720 G, respectively. The isotropic constants, Ao
and go, were identical to those found when this spin label moiety was attached to morphine
(A) as would be expected.
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FIGURE 4 Comparison of the interaction of commercial and synthesized 3-SLM with morphine
antibody. Equimolar quantities of commercial (FRAT reagent B) (left) and synthesized (right)
3-SLM were added to morphine antibody (FRAT reagent A) such that all morphine binding sites
were occupied. (Titrations used to determine this equivalence point are not illustrated.) Ali-
quots of each antibody solution were then combined with morphine standard solutions having
concentrations of 0.5, 5.0, and 50 ug/ml, respectively. The partial ESR first derivative spectra
shown illustrate the increase in amplitude of the M = + I line as progressively more 3-SLM is
displaced from the antibody. The ESR spectra depicted were obtained using a TE104 dual cavity
with the samples in capillary tubes. The temperature was held at 21'. The incident power was
40mW and the modulation amplitude was 2 G.
TrIia = 1.2 x 10-9 s) indicating inhibition of the nitroxide's tumbling rate by the 285
dalton morphine molecule.
Fig. 4 illustrates that added free morphine displaces commercial SLM and synthe-
sized 3-SLM from morphine antibody' in a nearly identical manner. The slight differ-
ences in line amplitude may be related to the variability encountered in titrating the
antibody. The M = +1 line of the nitroxide triplet is illustrated. Because the line
amplitude is temperature dependent (19), a constant temperature of 210 was main-
tained for these determinations.
Preliminary Biological Studies
In Vivo Injections. In the first set of experiments, animals were injected i.p.
with 3-SLM at a dose of 24 mg/kg morphine equivalents. None of the animals demon-
strated any grossly apparent signs (behavioral or physiological) of central nervous
system effects.
In the six mice receiving 3-SLM intracerebrally at 0.30 mg/kg morphine equivalents
and observed for grossly apparent drug effects, all demonstrated lethargy, staggering
gait, and moderate respiratory depression. None of the six control animals demon-
5Morphine antibody can recognize substituents on C-6 and the ring nitrogen as well as the degree of satura-
tion of the C-7 to C-8 bond (18).
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strated similar effects. The duration of the observed effects varied from 15 min to 1 h.
Thus, even though the bulky spin label group can orient itself on the postulated back-
side of morphine, it has a marked effect on morphine's pharmacology, possibly on its
transport into the central nervous system or on the rate at which it is metabolized
after i.p. injection.
The next set of experiments was carried out to determine whether 3-SLM could be
detected in brain tissue after injection directly into a brain ventricle and whether
3-SLM injected i.p. could be detected in whole brain tissue homogenate. In those rats
receiving 0.05 mg/kg morphine equivalents of 3-SLM intraventricularly, 3-SLM could
be detected by ESR in the whole brain homogenate. However, when 3-SLM was
administered i.p. at 50 mg/kg, no 3-SLM was detectable in brain tissues isolated under
the same experimental conditions. The latter animals did have readily detectable levels
of 3-SLM in homogenates of nonperfused heart and liver. No attempt was made to
determine whether the spin label detected in these tissues was attached to morphine.
The apparent absence of 3-SLM in brain tissue after i.p. administration could have
been due to an enhanced metabolism, an inability of 3-SLM to cross the blood-brain
barrier, a selective reduction of nitroxide by brain tissues or an insufficient concentra-
tion of 3-SLM in brain tissues for ESR detection (- 10' M). If, like codeine, 3-SLM
were 0-dealkylated to morphine (20), i.p. administration should have produced a
pharmacological effect. Enhanced metabolism to the glucuronide would have negated
this effect. Reduction of the majority of the nitroxide radicals appears unlikely in view
of the fact that the spin label was detectable in brain tissue after intraventricular ad-
ministration. In regard to the possibility that 3-SLM may not cross the blood-brain
barrier, it is interesting to note the structural similarity between 3-SLM and morphine
glucuronide (Fig. 5). Hepatic morphine detoxification involves addition of the polar
glucuronide moiety at the 3-position which inhibits passage through the blood-brain
barrier. However, because the nitroxide moiety is relatively nonpolar compared to the
sugar moiety, the two forms of morphine although sterically similar probably differ
markedly in lipid solubility. It is, however, reasonable that 3-SLM would penetrate the
barrier less readily than free morphine.
In Vitro Synaptosomal Binding Studies
In order to study 3-SLM binding by an opiate receptor, we isolated whole brain synap-
tosomes which contain a high concentration of specific opiate receptors and bind both
opiates (21-23) and opiate antagonists (24). This in vitro system was also selected so
that the spin labeled opiate concentration could be in a pharmacologically meaningful
range and yet be detectable with ESR. Goldstein et al. (25, 26) have found that the
levorphanol concentration in brain water of mice exhibiting maximal opiate analgesia
is approximately 10-6 M. Thus, a total 3-SLM concentration of 10-6 M in the synapto-
some preparation was employed.
The results of the incubation experiments outlined above are presented in Table I.
The ESR spectra observed were similar to that of Fig. 3 A and showed no significant
changes in 3-SLM rotational correlation time after the various incubations. A reduc-
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FIGURE 5 Comparison of the molecular conformations of spin labeled morphine and morphine
and morphine glucuronide. Corey-Pauling-Koltun (CPK) molecular models of 3-SLM (left)
and morphine glucuronide (right) illustrate that both the molecular conformation and the separa-
tions of the charged groups (dotted line) are similar. Below the CPK models, the conventional
structures of the two molecules provide orientation. See text for further discussion.
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TABLE I
SPECIFIC BINDING OF SPIN LABELED MORPHINE BY RAT BRAIN SYNAPTOSOMES
A. Amplitude of theM - -1 line* (cm) according to incubation conditiont
Run A B C D
1 9.2 10.8 6.7 8.7
2 11.1 12.5 8.3 11.3
3 6.4 8.0 5.2 5.8
4 7.8 8.7 4.6 7.9
B. Specific binding of 3-SLM by synaptosomes'
Binding Binding at
23' prevented
Protein Total Total 0° 23° by NAL§
conc. 3-SLM [(B - C)/B] [(B - A)/B] [(A - C)/BI [(D - C)/BJ
mg/ml mnol/ml % pmol/mg % pmol/mg % pmol/mg % pmol/mg
1 8.4 1.012 38.0 29.3 14.8 11.4 23.1 17.8 18.5 14.3
2 9.0 1.012 33.6 24.2 11.2 8.1 22.4 16.1 24.0 17.3
3 10.0 0.996 35.0 22.3 20.0 12.7 15.0 9.6 7.5 4.8
4 10.5 0.997 47.1 28.6 10.3 6.3 36.8 22.4 37.9 23.0
Mean + standard error 26.1 f 1.7 9.6 1.5 16.5 + 2.6 14.9 + 3.8
Because of differences in spectrometer tuning and in 3-SLM concentration between runs, only line am-
plitude variations within a run may be compared.
tKey to incubation conditions:
Group Constituents and treatment
A I ml SYN,§ I nmol 3-SLM-0
B I ml SYN, I nmol 3-SLM, 1 smol NAL-0°
C I ml SYN, 5 min at 23° + I nmol 3-SLM, 10 min at 23° 0°
D I ml SYN, I ;tmol NAL, 5 min at 23' + I nmol 3-SLM, 10 min at 23°-0
1Line amplitudes tabulated in A were converted to percent available 3-SLM bound under the conditions
described using the relations noted. The letters, A-D, refer to the amplitude of the M = - I line of the ESR
spectra of the four incubation groups having the same letters. "B" is used in these calculations as a mea-
sure of free 3-SLM in the presence of synaptosomes with no specific binding (see text). The concentration
of specifically bound 3-SLM expressed as picomoles per milligram protein was calculated assuming that
36% of the total 3-SLM was nonspecifically bound (see text). For example, run 1: total 3-SLM is 1.012
nmol, (0.36)(1.012) = 0.365 nmol 3-SLM nonspecifically bound and the remainder, 0.645 nmol, available
for specific binding. Of this 645 pmol, 38% or 246 pmol was specifically bound (total specific binding) by
synaptosomes with 8.4 mg protein. Hence, the total specific binding was 246/8.4 or 29.3 pmol 3-SLM/mg
protein. Because the extent of nonspecific binding has only been estimated and could vary with each syn-
aptosome preparation, the specific binding values (pmol/mg) must be considered approximations. They
are presented to give the reader a clear idea of precisely what is being measured.
§NAL = nalorphine HCI, SYN = synaptosomes in 0.32 M sucrose at pH 7.5.
tion of theM = -1 line amplitude6 was interpreted as a decrease in the concentration
of free 3-SLM due to synaptosome binding (27, 28). The baseline for no specific7
6 Either of theM = 4 1 lines can be monitored since each is located in a field region little perturbed by the
spectrum of strongly immobilized spin label.
7 Since 3-SLM specific binding was not measured by using morphine analog stereoisomers, e.g., levorphanol
vs. dextrorphan, the observed binding cannot strictly be termed stereospecific (1), but is pharmacologically
specific (29).
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3-SLM binding was provided by the synaptosome samples held at 00 with 1 mM nalor-
phine and 1 AM 3-SLM (group B). The high concentration of nalorphine as well as its
greater affinity for the narcotic receptor (three times morphine [24]) should prevent
specific binding of 3-SLM. However, nonspecific binding of 3-SLM would be expected
to occur under these conditions, so that the amplitude of the M = -1 line cannot be
equated with the total concentration of 3-SLM in the sample. Studies in model sys-
tems have indicated that the nonspecific binding of 3-SLM is primarily associated with
lipids, is minimal with proteins and is not influenced by nalorphine at these relative
concentrations (unpublished results, this laboratory).
Since previous studies (21, 24) had demonstrated that a significant part of specific
opiate binding in brain subfractions can occur at 04%, the specific binding both at 0°
and after incubation at 23° was measured. The extent of specific binding is expressed
both in terms of percent of 3-SLM available for such binding and as picomoles per
milligram protein using an estimate of nonspecific binding.8 Thus, the following com-
ments on the interaction of 3-SLM with synaptosomes can be made on the basis of the
data presented in Table I. About 38% of the 3-SLM that does not experience non-
specific binding was specifically bound after incubation for 10 min (26.1 pmol/mg).
Since 14% of this 3-SLM pool available for receptor site binding interacts at 0° (9:6
pmol/mg), the remaining 24% must bind in a temperature dependent process (16.5
pmol/mg). Preincubation of synaptosomes with 1 mM nalorphine prevents essentially
all temperature-dependent 3-SLM binding (16.5 i 2.6 vs. 14.9 ± 3.8 pmol/mg).
No spectral indications of strongly immobilized 3-SLM as previously demonstrated
with morphine antibody (5, 19) were observed. Unequivocal ESR identification of
3-SLM bound by the synaptosome opiate receptors requires that greater than about
85% of the label be immobilized. When less label than this is bound, the signal of the
free label can dominate the composite spectrum (27).
Selective reduction of the nitroxide label during the course of these studies was not
indicated. Spin labeled morphine bound to synaptosomes could be displaced into
solution by addition of a 102- IO' molar excess of levorphanol or nalorphine directly to
the ESR flat cell containing the synaptosome+3-SLM complex. The increase in ESR
line amplitude then observed approximately corresponded to the amount of 3-SLM
specifically bound.
A complete kinetic study to delineate fully the effects of incubation time and tem-
8 Both binding and viscosity changes can cause an alteration in line amplitude. If synaptosomes were omitted
from samples made up in 0.32 M sucrose to measure line amplitude in the absence of binding, the viscosity
change caused by synaptosomes would not be accounted for. It is feasible that the zero-binding limit can
be evaluated by extrapolating "B" line amplitudes to zero protein concentration. An analysis of this nature
showed that the logarithm of the M = + I line amplitude varied linearly with synaptosomal protein concen-
tration and on extrapolation to zero protein concentration, gave a value equal to that determined in 0.32 M
sucrose. The logarithm of the M = - I line amplitude did not vary linearly with protein concentration as
might be expected from its considerably greater sensitivity to viscosity compared to theM = + I line (27). By
assuming that theM = + I line amplitude reflected binding only, we obtained an estimate for maximum non-
specific binding. At the mean synaptosomal protein concentration of the four runs, 9.5 mg/ml, a maximum
of about 36% of the total 3-SLM was nonspecifically bound. Since about 38% of the remaining 3-SLM or
24% of the total was specifically bound, the nonspecific to specific binding ratio was about 1.5/1.
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perature and synaptosome concentration for this model system was not within the
scope of the preliminary study reported here. At temperatures approaching 370, a less
stable interaction was noted. Also, as might be expected, when synaptosomes were
heated at 100° for 5 min, no subsequent specific binding of 3-SLM could be demon-
strated. Specific binding could also be completely eliminated by hypotonic lysis of the
synaptosomes in 3 mM Tris buffer prior to analysis. As was found for the model lipid
and protein systems mentioned above, nalorphine had no effect on free 3-SLM concen-
tration in such lysed preparations at 00, 23° or when added directly to the flat cell. The
amount of specifically bound 3-SLM increased with synaptosomal protein concentra-
tion up to 5 mg/ml above which point a constant maximum was obtained. The data
reported in Table I were obtained in this region ofmaximum 3-SLM binding.
Specific binding of3-SLM could also be demonstrated in whole brain homogenates
using a similar experimental regimen. In parallel experiments we found that tempera-
ture dependent specific binding at 230 was about 10% of that exhibited by synapto-
somes with approximately the same protein concentration, although specific binding at
00 was nearly the same. Specific binding could also be completely eliminated by hypo-
tonic lysis of the brain homogenate.
DISCUSSION
This study demonstrates that an ESR spin label technique can complement radiotracer
studies of the narcotic receptor site. The concentration of unbound spin label can be
determined in the presence of a wide range of bound spin label concentrations (3-5, 19)
and specific opiate binding can be examined in vitro without separating the bound and
free labeled opiate.9 In the case of 3-SLM binding by morphine antibody, strong
immobilization of the label causes line broadening (5, 19) with a more than 40-fold
reduction of the M = 0 line amplitude and essential disappearance of absorption at the
magnetic fields ofM = + 1. If the spin label is only partially immobilized by binding, a
similar 20-fold decrease in the M = 0 line amplitude is noted (27). Thus, the decrease
in concentration of free spin labeled material can easily be monitored, although defini-
tive analysis of the bound spin label requires that greater than about 85% of the label
be immobilized. The above phenomena have been used to demonstrate that the extent
of specific binding of 3-SLM in vitro is temperature dependent in whole brain synapto-
somes and whole brain homogenate and that this binding can be prevented or the
bound 3-SLM can be displaced by an opiate agonist (levorphanol) or antagonist
(nalorphine).
In vivo investigations suggest that 3-SLM cannot cross the blood-brain barrier, but
has a pharmacologic effect is injected intracerebrally. Goldstein et al. (26) have re-
9The disparity between the concentration of specific opiate receptors reported here ( - 26 pmol/mg protein;
assuming a 1.5/1 nonspecific to specific binding ratio) and those determined previously (22, 24, 30, 31) using
radioactive labels (-0.1 pmol/mg protein) should be noted. It may in part be due to the fact that postincu-
bation washing to remove unbound radioactive opiate, which may destroy evidence of weak binding (1,2 1), is
not required in our assay.
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ported that when the whole brain concentration of levorphanol is about 4 sg/g brain
in nontolerant mice, the depressant actions of the opiate are dominant. When mice in
the current study were given intracerebral injections of 3-SLM at a dose in morphine
equivalents of 12.5 ug/g brain, lethargy and respiratory depression were observed. Al-
though any comparison is at best qualitative, the observed effect is that which might be
expected for an opiate with about 4-10 times less pharmacological activity than levor-
phanol.
In addition to the general findings of the synaptosome studies just mentioned, some
specific discussion is warranted. The lack of an observed change in rotational correla-
tion time in the various incubation conditions indicates that free 3-SLM dominates our
spectra. We cannot determine the degree of immobilization of the spin label when
3-SLM is bound. Even moderate immobilization of the label, as mentioned above,
would cause the changes in line amplitude (and therefore concentration) of unbound
3-SLM reported. We can rule out, however, complete binding of the 3-SLM with only
very slight immobilization of the label as this would have caused a detectable increase
in rotational correlation time.
In this study about 37% of the total specific binding took place at 00. Hug and
Oka (21), who did not distinguish between specific and nonspecific binding, found
that 72% of the total [3H]dihydromorphine was bound by isolated synaptosomes at 0°.
Pert and Snyder (24), on the other hand, observed that in whole brain homogenate,
only 10% of the total [3H]naloxone specific binding occurred at 4°. Our studies with
whole brain homogenate are insufficient for a quantitative comparison but indicate
that about 75% of the total specific binding observed occurred at 0°.
The ability to interact with the narcotic receptor apparently parallels opiate
pharmacological activity (22, 24, 30). Thus preparation of spin labeled opiates with
high pharmacologic potency would be advantageous for using these compounds as
probes to characterize receptor sites. In this regard, the 6-, 7-, or 8-SLM derivatives
might be more pharmacologically potent than 3-SLM for two reasons. First, if the
Beckett-Casy model is essentially correct, then even though the spin label moiety can
assume a "back-side" position in 3-SLM, there is an alteration at the edge of the pro-
posed ir-orbital binding group. Introduction of the label at a greater distance from this
region would be more favorable. Second, codeine, which is similar to 3-SLM in that
the phenolic hydroxy group is altered, has a markedly lower affinity for the opiate
receptor than does morphine (24, 31).
An intriguing opportunity which spin label techniques offer to studies of the narcotic
receptor is to analyze the ESR spectrum of bound spin labeled opiate probes to charac-
terize the binding interaction and the geometry of the receptor site.
A cursory description of the synthetic technique was presented at the International Conference on Electron
Spin Resonance and Nuclear Magnetic Resonance in Biological Systems, December 1972, New York, and
appeared in (1973) Ann. N. Y. Acad. Sci. 222:1087.
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